Hyderabad, Aug 11 (PTI) Dr Reddys Laboratories Ltd on Tuesday announced the launch of a generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension in the American market, following approval from the US Food and Drug Administration (USFDA).

Ciprodexis used in adults and children 6 months of age or older to treat certain types of infections caused by certain germs called bacteria.

Also Read | Samsung Galaxy Note 20 Mystic Blue Colour Variant Introduced in India at Rs 64,999.

"We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients.

At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form," Marc Kikuchi, Chief Executive Officer of North America Generics, Dr Reddy's said in a release.

Also Read | Aadhaar Card: How to Download E-Aadhaar by Using Registered Mobile Number Online at eaadhaar.uidai.gov.in.

The Ciprodex brand had US sales of approximately USD 453 million MAT (moving annual turnover) for the most recent 12 months ending in June 2020 , the drug maker said, quoting market data.

Dr Reddys Ciprofloxacin 0.3 per cent and Dexamethasone 0.1 percent Otic Suspension, USP, is available as 7.5 ml fill in a 10 ml bottle, it said.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)